Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 7/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119337 | 1.00 | AAK1 (0.37) | AAK1CYP17A1MAPK14LCKSYK | |
| SCHEMBL5111921 | 0.87 | MAPK14 (0.41) | MAPK14LCKGRM4HDAC3HDAC1 | |
| SCHEMBL5111926 | 0.87 | MAPK14 (0.41) | MAPK14LCKGRM4HDAC3HDAC1 | |
| SCHEMBL5126091 | 0.84 | AAK1 (0.38) | AAK1MAPK14GRM4HDAC3HDAC1 | |
| SCHEMBL5126085 | 0.84 | AAK1 (0.38) | AAK1MAPK14GRM4HDAC3HDAC1 | |
| SCHEMBL5203135 | 0.70 | NPC1 (0.47) | AAK1CYP17A1ATR | |
| SCHEMBL3888502 | 0.69 | IGF1R (0.42) | CYP17A1MAPK14HDAC1 | |
| SCHEMBL2300386 | 0.68 | ATR (0.47) | AAK1CYP17A1LCKATR | |
| SCHEMBL17518970 | 0.68 | ATR (0.53) | AAK1CYP17A1LCKATR | |
| SCHEMBL17518971 | 0.68 | ATR (0.47) | AAK1CYP17A1SYKATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | MAPK13, MMP13, MAPK3 | AAK1 2433/4885CYP17A1 2023/4885MAPK14 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.